Abstract
Experimental evolution studies have shown that weak antibiotic selective pressures (i.e., when the antibiotic concentrations are far below the minimum inhibitory concentration, MIC) can select resistant mutants, raising several unanswered questions. First, what are the lowest antibiotic concentrations at which selection for de novo resistance mutations can occur? Second, with weak antibiotic selections, which other types of adaptive mutations unrelated to the antibiotic selective pressure are concurrently enriched? Third, are the mutations selected under laboratory settings at subMIC also observed in clinical isolates? We addressed these questions using Escherichia coli populations evolving at subMICs in the presence of either of four clinically used antibiotics: fosfomycin, nitrofurantoin, tetracycline, and ciprofloxacin. Antibiotic resistance evolution was investigated at concentrations ranging from 1/4th to 1/2000th of the MIC of the susceptible strain (MICsusceptible). Our results show that evolution was rapid across all the antibiotics tested, and selection for fosfomycin- and nitrofurantoin-resistant mutants was observed at a concentration as low as 1/2000th of MICsusceptible. Several of the evolved resistant mutants showed increased growth yield and exponential growth rates, and outcompeted the susceptible ancestral strain in the absence of antibiotics as well, suggesting that adaptation to the growth environment occurred in parallel with the selection for resistance. Genomic analysis of the resistant mutants showed that several of the mutations selected under these conditions are also found in clinical isolates, demonstrating that experimental evolution at very low antibiotic levels can help in identifying novel mutations that contribute to bacterial adaptation during subMIC exposure in real-life settings.
Keywords: antibiotic resistance, selection, Escherichia coli, media adaptation, subMIC, fitness
Introduction
Preexisting and de novo-generated resistant mutants can be selected at very low antibiotic concentrations that are well below the minimum inhibitory concentration (subMIC) of a given antibiotic (Davies et al. 2006; Olofsson et al. 2007; Gullberg et al. 2011, 2014; Westhoff et al. 2017; Wistrand-Yuen et al. 2018; Sanz-García et al. 2020; Stanton et al. 2020; Gu et al. 2021). These results imply that the selection of antibiotic resistance is likely to also occur in many environments where antibiotics are present at low concentrations due to anthropogenic pollution, for example in soil, surface water, and wastewater treatment plants, as well as in certain tissues/compartments in antibiotic-treated humans and animals (Baquero and Negri 1997; Kümmerer and Henninger 2003; Berge et al. 2005; Chee-Sanford et al. 2009; Heuer et al. 2011; McManus 2014; Gao et al. 2015; Shenje et al. 2015; Thabit et al. 2019). Although these studies have demonstrated that subMIC antibiotic levels can indeed select for resistance, the potential for the emergence of clinically relevant mutations under such selection regimes remains largely unclear. A few studies have shown the emergence of resistance mutations that are found in clinical isolates under subMIC antibiotic exposure, for example, for fluoroquinolone (Sanz-García et al. 2022) and streptomycin (Wistrand-Yuen et al. 2018) subMIC levels selected for mutations in the fluoroquinolone target DNA gyrase (gyrA) and the gidB gene (encodes an enzyme that modifies the ribosome), respectively. These limited number of studies accentuate the need to systematically determine if clinically relevant resistance mutations are selected under subMIC exposure and to examine the nature of these mutations.
Furthermore, since selection for resistance at antibiotic levels much below the MIC is weak, other concurrent selective pressures present in these environments, such as adaptation to the specific growth conditions (energy/carbon sources, temperature, and pH), as well as compensatory evolution to reduce the fitness costs of any emerging resistance mutations (Björkman et al. 2000; Moura de Sousa et al. 2015; Gifford et al. 2016), will also influence the evolutionary trajectory. These considerations raise questions regarding the relative importance of bona fide resistance mutations and media adaptive mutations, respectively, at subMIC levels and also whether certain mutations can concomitantly increase resistance and confer media adaptation. Precedent for the existence of the latter type of mutations comes from two previous studies which showed that a small fraction of mutants selected for adaptation to the specific growth media, in the absence of any antibiotic exposure, coincidentally also showed increased resistance to some antibiotics (Knöppel et al. 2017; Lamrabet et al. 2019). These results suggest that there exist a pool of mutations that pleiotropically can cause both increased resistance and media adaptation, and thus, they could potentially play a role during subMIC evolution. Regarding compensatory evolution at subMIC, to the best of our knowledge, only a single study utilizing Streptomyces coelicolor and subMIC exposure of streptomycin (Westhoff et al. 2017) has suggested the role of compensatory mutations in the selection of resistant mutants.
For this study, we examined antibiotics that are clinically relevant and are used to treat human and animal infections caused by E. coli, including nitrofurantoin, ciprofloxacin, and fosfomycin (Wagenlehner et al. 2013; Pérez et al. 2014; Huttner et al. 2015; Papich 2017; Huttner et al. 2018; Kot 2019; Drekonja et al. 2021; Leuin et al. 2021). We also included the antibiotic tetracycline, which is used for other types of infections (Roberts 2003) and is commonly found at low concentrations in many natural environments (Liu et al. 2018; Song et al. 2021; Wang et al. 2021). For each of these antibiotics, the selection was carried out over a wide-range of subMIC antibiotic levels to determine the minimal selective concentration (MSCs), where MSC is defined as the lowest antibiotic concentration where the fitness cost of the resistance is balanced by the antibiotic-conferred selection for the resistant mutant (Gullberg et al. 2011). Individual resistant mutants were characterized with regard to their resistance level, relative fitness (in single batch culture and by competitions), and cross-resistance to other antibiotics, and were whole-genome sequenced to identify the genes and mutations that conferred increased resistance and/or growth-media adaptation.
Results
Selection of Resistant Mutants at subMIC of Antibiotics
We serially passaged eight lineages of E. coli K-12 MG1655 at different subMIC antibiotic concentrations of fosfomycin, tetracycline, nitrofurantoin, and ciprofloxacin to determine the lowest antibiotic concentrations that would result in the selection of resistant mutants (fig. 1). As a control, bacteria were also serially passaged in the absence of antibiotics and under these conditions, no increase in resistance was observed. The antibiotic concentrations used in our experiments ranged from 1/4th of MICsusceptible to 1/2000th of MICsusceptible (where MICsusceptible refers to the MIC of the susceptible E. coli K-12 strain for each antibiotic). After every ∼30 generations of serial passage, approximately 106 bacterial cells were plated from each lineage on plates containing antibiotic concentrations of 2 × -, 4 × -, 8 × -, and 16 × MICsusceptible to determine the frequency of resistant mutants in the evolving population. For all the antibiotics tested, we observed an increase in the frequency of resistant mutants over the course of the experiment, although the rate of increase and the lowest concentration at which selection for resistant mutants observed is antibiotic-specific (supplementary fig. S1, Supplementary Material online). For example, fosfomycin selection occurred rapidly and fixation of high-level resistant mutants was observed at concentrations of 1/20th of MICsusceptible at ∼30 generations, while an increase in the frequency of resistant mutants continued to occur even at concentrations below it, although at a slower rate. Despite this difference in rates, the selection of high-level fosfomycin-resistant mutants (ability to grow at an antibiotic concentration of 16 × MICsusceptible) was observed at all the different subMICs of fosfomycin, although they only reached fixation at subMICs of 1/50th of MICsusceptible and above. On the other hand, the selection of resistant mutants for ciprofloxacin was observed only at concentrations of 1/4th of MICsusceptible and 1/10th of MICsusceptible after ∼200 generations of cycling, with high-level resistant mutants (ability to grow at an antibiotic concentration of 8 × MICsusceptible) only being selected at 1/4th of MICsusceptible. For the remaining two antibiotics, the rate of enrichment of resistant mutants ranges between these two extremes (supplementary fig. S1, Supplementary Material online). Thus for tetracycline, high-level resistant mutants (ability to grow at an antibiotic concentration of 16 × MICsusceptible) were observed at subMICs of 1/50th of MICsusceptible and above, but were only fixed in the population at concentrations of 1/4th of MICsusceptible, while resistant mutants that could grow at 4 × MICsusceptible were observed at all the subMICs tested, and reached fixation at concentrations of 1/200th of MICsusceptible and above. For nitrofurantoin, mutants that could grow at concentrations of 16 × MICsusceptible were observed only at 1/4th of MICsusceptible, but did not reach fixation during the course of the experiment, while the mutants that could grow at 4 × MICsusceptible were observed at all the subMICs tested.
Minimal Selective Concentrations for Different Antibiotics and Resistance Levels of Mutants
Selection of resistant mutants occurs over a broad range of subMICs in our experiments, allowing us to determine the minimum selective concentration (MSC) for each of the four antibiotics used in our study (fig. 2, Table 1 and supplementary Table S2, Supplementary Material online). The lowest antibiotic concentration at which the selection of resistant mutants was observed is reported as the MSC in our dataset. To determine the MSC for resistant mutants with different levels of resistance, we screened for the emergence of mutants at antibiotic concentrations of 2 × -, 4 × -, 8 × -, and 16 × of MICsusceptible. As summarized in figure 2, depending on the antibiotic, the lowest concentration at which resistant mutants are selected (i.e., MSC) is either 1/20th (ciprofloxacin), 1/200th (tetracycline), or 1/2000th (fosfomycin and nitrofurantoin) of MICsusceptible. In addition, and as expected, the higher the antibiotic concentration used for selection, the higher the resistance level of the resistant mutants. This was observed for nitrofurantoin, tetracycline, and ciprofloxacin, but not for fosfomycin, where even the lowest concentration (1/2000th of MICsusceptible) was selected for mutants that could grow at all tested concentrations. Importantly, the subMIC exposure resulted in the selection of mutants with resistance levels above the clinical break-point (fosfomycin and nitrofurantoin) or just below (ciprofloxacin), whereas for tetracycline, no clinical breakpoint has been set for E. coli (fig. 3).
Table 1.
MSC values were calculated based on the enrichment of resistant mutants in evolution experiments at subMICs of antibiotics.
Clinically Relevant Resistance Mutations Can be Selected at subMICs of Antibiotics
To identify the resistance mutations that were enriched in these experiments, we, whole-genome sequenced a subset of resistant clones isolated at the end-point of the evolution experiment for each antibiotic. Thus, eight clones were whole-genome sequenced from lineages each evolving at antibiotic concentrations of 1/4th and 1/200th of MICsusceptible. For fosfomycin, resistant clones selected at antibiotic concentrations of 1/2000th of MICsusceptible were also whole-genome sequenced, while ciprofloxacin-resistant clones selected at 1/10th of MICsusceptible (instead of 1/200th of MICsusceptible) were whole-genome sequenced. To ensure that we sequenced mutants with potentially different resistance mutations, we first determined the growth rate of the isolated mutants at different concentrations of the appropriate antibiotic. This allowed us to choose mutants with different growth rates (and potentially different types of mutations) for whole-genome sequencing (supplementary fig. S2, Supplementary Material online). We also determined if any of the selected mutants were mutator strains by performing the Luria–Delbruck fluctuation test with rifampicin resistance as the test marker. If the resistant clone was identified as a mutator strain then, wherever possible, it was not whole-genome sequenced because of the difficulty in making any meaningful genotype–phenotype correlations in mutants carrying many mutations.
This analysis demonstrates the presence of multiple clinically relevant antibiotic resistance mutations among the isolated resistant clones (fig. 4, supplementary fig. S3 and Table S3, Supplementary Material online). For fosfomycin, this included mutations in genes glpT (glycerol 3-phosphate:phosphate antiporter), uhpT (hexose-6 phosphate:phosphate antiporter), uhpC (inner membrane protein sensing glucose 6-phosphate), and uhpA (transcriptional activator for genes encoding proteins sensing glucose 6-phosphate). Mutations in these genes have been shown to confer fosfomycin resistance by reducing fosfomycin uptake (Nilsson et al. 2003; Fu et al. 2015). Resistance to the antibiotic nitrofurantoin was linked to mutations in genes nfsA (nitroreductase), nfsB (nitroreductase), and a deletion in the intergenic region between the genes marA-marB (“multiple antibiotic resistance” genes). Proteins encoded by genes nfsA and nfsB are enzymes known to activate the inactive form of nitrofurantoin inside the cell, and mutations that result in the loss of function or reduced function in these genes would thus result in lower levels of the activated antibiotic inside the cell (Sandegren et al. 2008; Wan et al. 2021). Additionally, proteins encoded by the marA-marB genes are known to regulate the expression of genes involved in conferring antibiotic resistance and resistance to oxidative stress (Barbosa and Levy 2000; Chollet et al. 2002). Ciprofloxacin-resistant mutants included mutations in genes gyrA (DNA gyrase subunit A) and gyrB (DNA gyrase subunit B). These are the target genes for ciprofloxacin, and mutations in these genes result in reduced binding of ciprofloxacin to DNA gyrase (Lee et al. 2005; Garoff et al. 2020). Tetracycline-resistant mutants had mutations in the gene envZ (sensor histidine kinase). Although it is unclear how mutations in this gene confer resistance toward tetracycline, they have been shown to be clinically relevant for other antibiotics (Adler et al. 2016).
Both Increased Resistance and Media Adaptation Contribute to the Increased Fitness at subMIC of Antibiotics
Our experimental design allowed us to determine the contributions of resistance evolution and growth environment adaptation to the enrichment of mutants at the subMIC levels of antibiotics. To this end, we measured the relative fitness of 40 resistant mutants (isolated from the end-point of the evolution experiment) both in the presence and absence of the antibiotic by competition with the wild-type susceptible ancestral strain. Out of these 40 resistant mutants, 34 showed an increase in fitness both in the presence and absence of the antibiotic, one had higher fitness than the wild-type susceptible strain in the presence of the antibiotic but had the same fitness in its absence, and five showed a reduction in fitness under both these conditions (fig. 5). The latter observation is peculiar, but it most likely indicates the presence of non-transitive fitness interactions in our experiments (Paquin and Adams 1983; Rainey and Travisano 1998; Buskirk et al. 2020), such that a competition with the ancestral parent strain does not correctly reflect the fitness trajectory of the evolving population. These mutants were not investigated further.
To determine the contribution of increased antibiotic resistance to the increase in fitness among the remaining 35 resistant mutants, we calculated the difference between the selection coefficients measured in the presence and absence of the antibiotic (fig. 6). Out of the 35 resistant mutants investigated, 16 mutants showed a measurable and statistically significant effect of the presence of the antibiotic on fitness (fig. 6). Among the remaining 19 mutants, 13 did not have a value that was statistically different from 0. It is possible that in these 13 cases, the fitness advantage due to increased antibiotic resistance was too small to be measured by our competition assay. The difference between the selection coefficients for the remaining six mutants was statistically lower than 0, suggesting potentially complex interactions between mutations conferring resistance and those conferring adaptation to the growth environment. Despite this complexity, our data convincingly demonstrate that under these conditions, there is concomitant selection for increased resistance and adaptation to the growth environment.
We also investigated the growth curves for each of these 35 resistant mutants to determine the relative contribution of an altered exponential growth rate and/or growth yield (population density in stationary phase) to increased fitness at subMICs of antibiotics (fig. 7A and B). A majority of the resistant mutants showed a higher relative growth yield both in the presence and absence of the antibiotic (when compared with the susceptible ancestral strain). For a small subset of mutants, we also observed a higher relative exponential growth rate for the resistant mutants both in the presence and absence of the antibiotic. Overall, these findings suggest that selection for increased yield was the predominant adaptive response during these serial passage conditions. We further investigated the correlation between increased resistance and these fitness components by comparing the relative exponential growth rate and growth yield for each mutant in the presence and absence of the antibiotic (fig. 7C). About half (18 out of 35) of the resistant mutants showed either an increased growth-yield (10 out of 35) or higher exponential growth rate (8 out of 35) that was due to the presence of the antibiotic, suggesting that selection for an increased growth yield and a higher exponential growth rate contributed equally toward resistance evolution at subMIC of antibiotics. Based on the present data, we cannot determine which type of mutants emerged first during selection.
Whole-genome sequencing of these resistant clones allowed us to identify the genetic changes that either contributed to the mutant becoming more resistant or better adapted to the growth environment. To determine the contribution of individual mutations, we first performed a literature search to identify mutations that are known to contribute to either resistance evolution or those that are known to result in adaptation to the growth environment (supplementary fig. S3 and supplementary Table S3, Supplementary Material online). In addition, we also reconstructed specific mutations to investigate them individually, including the mutations in genes kdpD (Arg511Lys), glpT (Asp88Glu), nfsA (Trp 212*), and envZ (Val49Ala). A total of 95 unique mutations were identified across 24 genes (fig. 8A–D). Based on the list of mutations identified from the literature and those that were reconstructed, 47 of them could potentially increase fitness by increasing resistance, while 48 of them could potentially confer adaptation to the growth environment (fig. 8A–D). Thus, at all the subMICs for the different antibiotics investigated, there was a selection for mutations conferring antibiotic resistance and growth environment adaptation.
Resistant Mutants Display Cross-resistance to Other Antibiotics
To determine if resistant mutants selected in our experiments were cross-resistant to other antibiotics, we measured the MICs of several different antibiotics for 83 resistant clones isolated from the end-point of our experiment. Cross-resistance was observed for clones selected on tetracycline and nitrofurantoin, where the former showed cross-resistance to fosfomycin and ciprofloxacin, and the latter demonstrated cross-resistance to fosfomycin. (supplementary Table S4, Supplementary Material online). The tetracycline-resistant mutants did not have any known mutations that confer high-level of fosfomycin resistance, whereas the nitrofurantoin-resistant mutants demonstrating cross-resistance to fosfomycin had a mutation in the uhpT gene, which has previously been implicated in fosfomycin resistance (Nilsson et al. 2003).
Discussion
The Minimal Selective Concentration for the Enrichment of de novo Resistance Mutations is Antibiotic Dependent
One main objective of this study was to determine the MSC for de novo resistance mutations for several antibiotics. The choice of antibiotics was motivated by clinical relevance and included fosfomycin, nitrofurantoin, and ciprofloxacin, which are all used for E. coli infections. Furthermore, clinically relevant resistance mutations are well characterized for these antibiotics, and in most cases, are a result of de novo occurring mutations. We also included tetracycline in our study because of its human and veterinary use (for other infections than those caused by E. coli) and common occurrence as an anthropogenic pollutant in several different environments. These four antibiotics also inhibit the growth of the bacterium in different ways by interacting with a diverse array of cellular processes. Thus, fosfomycin interacts with the MurA protein (Marquardt et al. 1994; Silver 2017) which is involved in peptidoglycan synthesis (cell-wall synthesis), ciprofloxacin interacts with the DNA gyrase enzyme (Barnard and Maxwell 2001; Mustaev et al. 2014) (DNA replication), tetracycline interacts with the ribosome (Chopra and Roberts 2001) (protein synthesis), while nitrofurantoin is a pro-dug that is activated to a free radical compound, which is suggested to have multiple targets within the cell (Jenkins and Bennett 1976; McOsker and Fitzpatrick 1994). Despite these different modes of actions, selection for antibiotic resistance was observed for all four antibiotics, but the MSC varied between the different antibiotics, both with regard to absolute concentration and relative to the MICsusceptible. Thus, in our experiments, we observed selection for fosfomycin and nitrofurantoin resistance mutations at antibiotic concentrations of 1/2000th of MICsusceptible, for tetracycline at 1/500th of MICsusceptible, and for ciprofloxacin-resistant mutants, selection was observed at an antibiotic concentration of 1/20th of MICsusceptible. Although this difference in MSCs for different antibiotics is in accordance with previously published studies (Sanz-García et al. 2022), the selection of clinically relevant resistance mutations for fosfomycin at 1/2000th of MICsusceptible is 10 times lower than the previously published values for MSCs for any antibiotic, accentuating the role of very low antibiotic concentrations as a selective force that enriches antibiotic resistance mutations in the environment.
Pervasive Selection of Clinically Relevant Mutations at subMICs of Antibiotics
Another important observation in this study was the pervasive selection of clinically relevant antibiotic-resistance mutations. Thus, mutations in the genes glpT and genes of the uhp operon were enriched under the subMICs of fosfomycin, mutations in genes nfsA and nfsB were selected under the subMICs of nitrofurantoin, mutations in genes gyrA and gyrB were selected under the subMICs of ciprofloxacin, and mutations in genes envZ were selected under the subMICs of tetracycline. Mutations in all these genes have previously been identified in clinical isolates with resistance to the respective antibiotics (Lee et al. 2005; Fu et al. 2015; Adler et al. 2016; Wan et al. 2021), except for the mutations in gene envZ which has been shown to be clinically relevant for other antibiotics (Adler et al. 2016). Thus, not only does this study demonstrate the selection of resistance mutations at extremely low concentrations, but also shows the selection of known clinically relevant mutations at these concentrations. Whole-genome sequencing analysis of multiple resistant mutants for each selective regime allowed us to determine that 47 unique mutations were observed across the above-mentioned targets (fig. 8A–D), further highlighting the pervasive selection for antibiotic resistance evolution at subMICs of antibiotics. This observation of a large number of mutations for increased resistance in clinically relevant target genes is worrisome, since similar antibiotic concentrations have been shown to be present in many different environments (Chee-Sanford et al. 2009; Heuer et al. 2011; McManus 2014; Gao et al. 2015). This suggests that several types of environments could serve as points of emergence and spread of these clinically relevant mutations. Furthermore, some of these mutations also conferred cross-resistance to other antibiotics than those they were selected on, making them especially problematic.
Adaptation to the Growth Environment Plays a Significant Role Under the subMIC Selection Regime
Another significant observation in our study was that besides the selection for increased resistance, adaptation to the growth environment (non-antibiotic related) was also a significant selective pressure. Thus, out of the 40 resistant mutants isolated from populations evolving at the subMICs of different antibiotics and where fitness was measured using competition experiments, 34 had higher fitness than the starting susceptible ancestral strain, even in the absence of the antibiotic. Whole-genome sequencing analysis of these resistant clones further shows that a total of 48 mutations could potentially increase fitness to the growth environment across these isolated resistant clones (fig. 8A–D). Intuitively, evolution under the subMIC selective regime could either proceed via the evolution of “specialist” types where adaptation against the antibiotics could represent one fitness peak, while adaptation to the growth environment might represent a second fitness peak. Alternatively, these environments could select for “generalist” strains that are adapted to both the environment and against the antibiotics, implying the occurrence of multiple selective sweeps, where the adaptive mutations for both these selective pressures occur in the same background, and/or that pleiotropic mutations that confer both resistance and media adaptation are selected (Knöppel et al. 2017; Lamrabet et al. 2019). Our results suggest that the evolutionary trajectory under the subMIC selective regime is inclined toward the selection of these generalist strains that are both resistant to the antibiotics and better adapted to the growth environment. Although several studies have shown the evolution of antibiotic resistance at low antibiotic concentrations, the occurrence of adaptation to the growth environment in such environments is usually unaccounted for. Our results imply that the selection of resistance mutations under the subMIC selection regime should be extended to include mutations that confer a general growth adaptation, and their role in influencing the evolutionary outcome when the antibiotic selection is weak, should further be investigated.
Materials and Methods
Bacterial Strains, Antibiotics and Growth Conditions
The bacterial strain Escherichia coli K-12 MG1655 was used as the susceptible parental strain for all the experiments. All the evolved resistant clones that were investigated in this study are listed in supplementary Table S1, Supplementary Material online. The antibiotics used for the evolution experiments included fosfomycin (MICsusceptible/Etest = 0.380 mg/L and MICsusceptible/broth micro.= 2 mg/L), tetracycline (MICsusceptible/Etest = 0.750 mg/L and MICsusceptible/broth micro.= 0.625 mg/L), nitrofuranotoin (MICsusceptible/Etest = 2 mg/L and MICsusceptible/broth micro.= 2.5 mg/L), and ciprofloxacin (MICsusceptible/Etest = 0.012 mg/L and MICsusceptible/broth micro. = 0.015 mg/L). The liquid and solid media used for all the experiments were Mueller–Hinton broth and Mueller–Hinton Agar (Becton Dickinson, MD, USA). All the experiments were performed at 37 °C. Glucose-6-phosphate was added to the media at a concentration of 50 mg/L for experiments involving fosfomycin.
Experimental Evolution Set-up and Determining the Emergence and Frequency of Resistant Mutants
The evolution experiments are performed in 96-well plates with eight lineages evolving per subMIC of the antibiotic (fig. 1). Eight replicate populations were also evolved in an antibiotic-free media and these served as control populations to determine the basal mutation rate for antibiotic resistance mutations. Several subMICs were used for each antibiotic, ranging from 1/4th of MICsusceptible to 1/2000th of MICsusceptible. Each well contained 200 μl of the appropriate media, and the bacteria was allowed to grow for 12 h after which 20 μl of grown cells was transferred to 180 μl of fresh media. This resulted in ∼3.3 generations of growth per cycle. At different time points during the course of the experiment (supplementary fig. S1, Supplementary Material online), 1 μl from each well was plated on antibiotic-containing plates to determine the occurrence and frequency of resistant mutants. Since we were broadly interested in the evolutionary dynamics at each subMIC of the antibiotic and not in the individual population-level dynamics, we mixed 1 μl each from four lineages that were evolving under the same condition and plated the mixture on a single antibiotic-containing plate. Thus, the frequency measured is a cumulative frequency of resistant mutants combined from four lineages. In each case, dilutions of this mixture were also plated on non-antibiotic-containing plates to approximate the population size for the lineages. MSC is reported as the lowest antibiotic concentration where enrichment of the resistant mutants was observed. Fixation of high-level resistant mutants was assumed when a bacterial lawn was observed on the antibiotic-containing plates. The antibiotic concentrations used to screen for resistant mutants ranged from 2×-MICsusceptible to 16×-MICsusceptible.
Growth Analysis of Resistant Mutants and Identification of Mutator Strains
Growth curves for all the resistant mutants were plotted by measuring growth using a BioscreenC analyzer at OD600, with measurements taken every 4 min. A 1:1,000 dilution of an overnight-grown culture was used to start the experiment, and the maximum exponential growth rate was calculated using the optical density (OD600) values between 0.02 and 0.09. Both the susceptible and resistant strains were grown in the absence and presence of different concentrations of the antibiotic to determine phenotypic differences between the resistant mutants. Six replicates were used in each case.
The potential occurrence of hyper-mutators among the isolated resistant mutants was determined by calculating the resistant mutant frequency for the antibiotic rifampicin. Briefly, 100 μl from an overnight-grown culture (for both resistant and susceptible strains) was plated on plates containing 100 μg/ml of rifampicin, and the plates were then incubated at 37 °C for 20 h. Four biological replicates were grown for each strain. In each case, dilutions were also plated on non-antibiotic-containing plates to determine the total number of cells being plated so as to calculate the frequency of rifampicin-resistant mutants.
Whole-genome Sequencing and Identification of Mutations
To identify resistance mutations and other adaptive mutations in the evolving populations, single clones were isolated and whole-genome sequenced. DNA extraction was done with 1 ml of overnight-grown cultures using the Epicenter DNA extraction kit following the manufacturer’s protocol. Illumina’s Nextera XT kit was used to make whole-genome DNA libraries (2 × 300) that were then sequenced on Illumina’s Miseq platform. Samples were dual-indexed and pooled together. The average whole-genome coverage per sample was 30 × . Analysis of the fastq files obtained from Miseq sequencing was performed using CLC genomics Workbench version 11. This tool was used to identify point mutations and small indels. To identify large deletions or transposon movements, the fastq files were also analyzed using Breseq (version 0.27.1a) (Deatherage and Barrick 2014). In each case, the reads were mapped onto the susceptible E.coli K-12 MG1655 strain that was also whole-genome sequenced and was the ancestral strain for all the evolved resistant mutants.
Determination of the Minimum Inhibitory Concentration
The MIC for different antibiotics for all the strains used in this study was determined using Etests, as per the instructions from the manufacturer (bioMérieux, Marcy l'Étoile, France). Briefly, overnight-grown cultures were diluted 1:20 in phosphate-buffered saline and then spread on Mueller–Hinton plates using a cotton swab. The Etests were then placed on the plates after which these were incubated at 37 °C for 16–18 h. Two biological replicates were done in each case.
Determining the Relative Fitness of Resistant Mutants by Competition Experiments
Competition experiments were performed by genetically tagging the different strains with genes encoding for fluorescent markers [yellow fluorescent protein (YFP) and blue fluorescent protein (BFP)]. Fluorescently labeled strains were grown overnight in Mueller–Hinton media in the absence of antibiotics, and then mixed in a 1:1 ratio to start the competition experiments. All competitions were performed in 96-well plates, where 20 μl of an overnight-grown culture was transferred to 180 μl of media each day, resulting in ∼3.3 generations per day. The frequencies for each strain were determined at the beginning of the experiment and after ∼10 generations. Strain frequencies at generations ∼20 and ∼30 were also measured for competition experiments involving nitrofurantoin-resistant mutants. Measurement of fluorescently tagged cells was done by making 40-fold dilutions of cultures from each well in phosphate-buffered saline. One Hundred Thousand cells were counted and the fraction of BFP and YFP positive cells was determined by flow cytometry (MACSQuant VYB, Miltenyi Biotec). Competition experiments for each strain were also performed by swapping the fluorescent markers so as to determine any fitness costs that might have been associated with the expression of the fluorescent proteins. The rate of change of the different strains is plotted as the natural log of the ratio of different strains at different timepoints. The slope of this line is calculated and reported as the selection coefficient. Eight replicates were used in each case. A two-tailed Student’s t-test was performed to test for statistically significant differences at P = 0.05.
Re-constructing Resistance-conferring Mutations Using λ-red Recombineering
A subset of the different resistance mutations was reconstructed using the λ-red recombineering technique (Yu et al. 2000). This involved using a 500 μl of an overnight-grown culture of E. coli K-12 MG1655 strain containing the pSIM5-Tet plasmid (Koskiniemi et al. 2011) (grown at 30 °C) and inoculating 50 ml of LB broth containing 10 mg/L of tetracycline. These cells were allowed to grow at 30 °C until the optical density (OD600) reached ∼0.2, after which they were transferred to a 42 °C shaking water bath for 20 min. At the end of 20 min, the cells were placed on ice for 5 min and then washed thrice with 10% glycerol. The pellet was resuspended in the residual 10% glycerol. A cat-sacB marker was then inserted in these cells at the desired location by electroporation. The cat-sacB marker, which was generated by PCR-amplification and consisted of over-hangs that were homologous to the site of insertion on the E. coli genome, consists of the selectable cat marker (allowing selection on chloramphenicol plates) and the counter-selectable sacB marker (resulting in cell-death in sucrose-containing plates). Once the marker is inserted at the desired position, similar steps are followed as above, to replace it with a single-stranded oligonucleotide containing the desired mutation and counter selecting them on plates containing 5% sucrose. Clones that can grow on sucrose-containing plates were isolated and the presence of the desired mutation was confirmed by Sanger sequencing.
Supplementary Material
Contributor Information
Catia Pereira, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Omar M Warsi, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Dan I Andersson, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Author Contributions
C.P, O.W., and D.I.A. designed the experiments. C.P. and O.W. carried out the experiments. O.W. and D.I.A. wrote the manuscript.
Supplementary Material
Supplementary data are available at Molecular Biology and Evolution online.
Acknowledgments
We would like to acknowledge funding from the Swedish Research Council to DIA (2021-02091) and OW (2021-04831), and the Wallenberg Foundation to DIA (KAW 2018.0168).
Data Availability Statement
The data underlying this article are available in the article and its online supplementary material. Fastq files with whole-genome sequences of resistant mutants have been uploaded at NCBIs SRA database with the bioproject accession number PRJNA906735.
References
- Adler M, Anjum M, Andersson DI, Sandegren L. 2016. Combinations of mutations in envZ, ftsI, mrdA, acrB and acrR can cause high-level carbapenem resistance in Escherichia coli. J Antimicrob Chemother. 71(5):1188–1198. [DOI] [PubMed] [Google Scholar]
- Baquero F, Negri MC. 1997. Selective compartments for resistant microorganisms in antibiotic gradients. BioEssays News Rev Mol Cell Dev Biol. 19(8):731–736. [DOI] [PubMed] [Google Scholar]
- Barbosa TM, Levy SB. 2000. Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA. J Bacteriol. 182(12):3467–3474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barnard FM, Maxwell A. 2001. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob Agents Chemother. 45(7):1994–2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Berge ACB, Atwill ER, Sischo WM. 2005. Animal and farm influences on the dynamics of antibiotic resistance in faecal Escherichia coli in young dairy calves. Prev Vet Med. 69(1–2):25–38. [DOI] [PubMed] [Google Scholar]
- Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science. 287(5457):1479–1482. [DOI] [PubMed] [Google Scholar]
- Buskirk SW, Rokes AB, Lang GI. 2020. Adaptive evolution of nontransitive fitness in yeast. Elife. 9:e62238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chee-Sanford JC, Mackie RI, Koike S, Krapac IG, Lin Y-F, Yannarell AC, Maxwell S, Aminov RI. 2009. Fate and transport of antibiotic residues and antibiotic resistance genes following land application of manure waste. J Environ Qual. 38(3):1086–1108. [DOI] [PubMed] [Google Scholar]
- Chollet R, Bollet C, Chevalier J, Malléa M, Pagès J-M, Davin-Regli A. 2002. mar Operon involved in multidrug resistance of Enterobacter aerogenes. Antimicrob Agents Chemother. 46(4):1093–1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev MMBR. 65(2):232–260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Davies J, Spiegelman GB, Yim G. 2006. The world of subinhibitory antibiotic concentrations. Curr Opin Microbiol. 9(5):445–453. [DOI] [PubMed] [Google Scholar]
- Deatherage DE, Barrick JE. 2014. Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. Methods Mol Biol. 1151:165–188. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Sousa JM, Sousa A, Bourgard C, Gordo I. 2015. Potential for adaptation overrides cost of resistance. Future Microbiol. 10(9):1415–1431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drekonja DM, Trautner B, Amundson C, Kuskowski M, Johnson JR. 2021. Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a Randomized Clinical Trial. JAMA. 326(4):324–331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fu Z, Ma Y, Chen C, Guo Y, Hu F, Liu Y, Xu X, Wang M. 2015. Prevalence of fosfomycin resistance and mutations in murA, glpT, and uhpT in methicillin-resistant Staphylococcus aureus strains isolated from blood and cerebrospinal fluid samples. Front Microbiol. 6:1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gao L, Hu J, Zhang X, Wei L, Li S, Miao Z, Chai T. 2015. Application of swine manure on agricultural fields contributes to extended-spectrum β-lactamase-producing Escherichia coli spread in Tai’an, China. Front Microbiol. 6:313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Garoff L, Pietsch F, Huseby DL, Lilja T, Brandis G, Hughes D. 2020. Population bottlenecks strongly influence the evolutionary trajectory to fluoroquinolone resistance in Escherichia coli. Mol Biol Evol. 37(6):1637–1646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gifford DR, Moss E, MacLean RC. 2016. Environmental variation alters the fitness effects of rifampicin resistance mutations in Pseudomonas aeruginosa. Evol Int J Org Evol. 70(3):725–730. [DOI] [PubMed] [Google Scholar]
- Gu Y, Huang L, Wu C, Huang J, Hao H, Yuan Z, Cheng G. 2021. The evolution of fluoroquinolone resistance in Salmonella under exposure to sub-inhibitory concentration of enrofloxacin. Int J Mol Sci. 22(22):12218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gullberg E, Albrecht LM, Karlsson C, Sandegren L, Andersson DI. 2014. Selection of a multidrug resistance plasmid by sublethal levels of antibiotics and heavy metals. mBio. 5(5):e01918–e01914. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D, Andersson DI. 2011. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 7(7):e1002158. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heuer H, Schmitt H, Smalla K. 2011. Antibiotic resistance gene spread due to manure application on agricultural fields. Curr Opin Microbiol. 14(3):236–243. [DOI] [PubMed] [Google Scholar]
- Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, de Tejada B M, Roux X, Shiber S, et al. 2018. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. JAMA. 319(17):1781–1789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. 2015. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 70(9):2456–2464. [DOI] [PubMed] [Google Scholar]
- Jenkins ST, Bennett PM. 1976. Effect of mutations in deoxyribonucleic acid repair pathways on the sensitivity of Escherichia coli K-12 strains to nitrofurantoin. J Bacteriol. 125(3):1214–1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knöppel A, Näsvall J, Andersson DI. 2017. Evolution of antibiotic resistance without antibiotic exposure. Antimicrob Agents Chemother. 61(11):e01495-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koskiniemi S, Pränting M, Gullberg E, Näsvall J, Andersson DI. 2011. Activation of cryptic aminoglycoside resistance in Salmonella enterica. Mol Microbiol. 80(6):1464–1478. [DOI] [PubMed] [Google Scholar]
- Kot B. 2019. Antibiotic resistance among uropathogenic Escherichia coli. Pol J Microbiol. 68(4):403–415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kümmerer K, Henninger A. 2003. Promoting resistance by the emission of antibiotics from hospitals and households into effluent. Clin Microbiol Infect. 9(12):1203–1214. [DOI] [PubMed] [Google Scholar]
- Lamrabet O, Martin M, Lenski RE, Schneider D. 2019. Changes in intrinsic antibiotic susceptibility during a long-term evolution experiment with Escherichia coli. mBio. 10(2):e00189-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee JK, Lee YS, Park YK, Kim BS. 2005. Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol Immunol. 49(7):647–653. [DOI] [PubMed] [Google Scholar]
- Leuin AS, Hartmann F, Viviano K. 2021. Administration of nitrofurantoin in dogs with lower urinary tract infections: 14 cases (2013–2019). J Small Anim Pract. 62(1):42–48. [DOI] [PubMed] [Google Scholar]
- Liu H, Yang Y, Sun H, Zhao L, Liu Y. 2018. Fate of tetracycline in enhanced biological nutrient removal process. Chemosphere. 193:998–1003. [DOI] [PubMed] [Google Scholar]
- Marquardt JL, Brown ED, Lane WS, Haley TM, Ichikawa Y, Wong CH, Walsh CT. 1994. Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry. 33(35):10646–10651. [DOI] [PubMed] [Google Scholar]
- McManus PS. 2014. Does a drop in the bucket make a splash? Assessing the impact of antibiotic use on plants. Curr Opin Microbiol. 19:76–82. [DOI] [PubMed] [Google Scholar]
- McOsker CC, Fitzpatrick PM. 1994. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother. 33(Suppl A):23–30. [DOI] [PubMed] [Google Scholar]
- Mustaev A, Malik M, Zhao X, Kurepina N, Luan G, Oppegard LM, Hiasa H, Marks KR, Kerns RJ, Berger JM, et al. 2014. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. J Biol Chem. 289(18):12300–12312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 47(9):2850–2858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Olofsson SK, Marcusson LL, Strömbäck A, Hughes D, Cars O. 2007. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother. 60(4):795–801. [DOI] [PubMed] [Google Scholar]
- Papich MG. 2017. Ciprofloxacin pharmacokinetics in clinical canine patients. J Vet Intern Med. 31(5):1508–1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paquin CE, Adams J. 1983. Relative fitness can decrease in evolving asexual populations of S. cerevisiae. Nature. 306(5941):368–370. [DOI] [PubMed] [Google Scholar]
- Pérez DS, Tapia MO, Soraci AL. 2014. Fosfomycin: uses and potentialities in veterinary medicine. Open Vet J. 4(1):26–43. [PMC free article] [PubMed] [Google Scholar]
- Rainey PB, Travisano M. 1998. Adaptive radiation in a heterogeneous environment. Nature. 394(6688):69–72. [DOI] [PubMed] [Google Scholar]
- Roberts MC. 2003. Tetracycline therapy: update. Clin Infect Dis. 36(4):462–467. [DOI] [PubMed] [Google Scholar]
- Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI. 2008. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother. 62(3):495–503. [DOI] [PubMed] [Google Scholar]
- Sanz-García F, Hernando-Amado S, Martínez JL. 2022. Evolution under low antibiotic concentrations: a risk for the selection of Pseudomonas aeruginosa multidrug-resistant mutants in nature. Environ Microbiol. 24(3):1279–1293. [DOI] [PubMed] [Google Scholar]
- Sanz-García F, Sánchez MB, Hernando-Amado S, Martínez JL. 2020. Evolutionary landscapes of Pseudomonas aeruginosa towards ribosome-targeting antibiotic resistance depend on selection strength. Int J Antimicrob Agents. 55(6):105965. [DOI] [PubMed] [Google Scholar]
- Shenje J, Ifeoma Adimora-Nweke F, Ross IL, Ntsekhe M, Wiesner L, Deffur A, McIlleron HM, Pasipanodya J, Gumbo T, Mayosi BM. 2015. Poor penetration of antibiotics into pericardium in pericardial tuberculosis. EBioMedicine. 2(11):1640–1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Silver LL. 2017. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med. 7(2):a025262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Song C, Zhang K-X, Wang X-J, Zhao S, Wang S-G. 2021. Effects of natural organic matter on the photolysis of tetracycline in aquatic environment: kinetics and mechanism. Chemosphere. 263:128338. [DOI] [PubMed] [Google Scholar]
- Stanton IC, Murray AK, Zhang L, Snape J, Gaze WH. 2020. Evolution of antibiotic resistance at low antibiotic concentrations including selection below the minimal selective concentration. Commun Biol. 3(1):467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. 2019. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 81:128–136. [DOI] [PubMed] [Google Scholar]
- Wagenlehner FME, Vahlensieck W, Bauer HW, Weidner W, Piechota HJ, Naber KG. 2013. Prevention of recurrent urinary tract infections. Minerva Urol Nefrol. 65(1):9–20. [PubMed] [Google Scholar]
- Wan Y, Mills E, Leung RCY, Vieira A, Zhi X, Croucher NJ, Woodford N, Jauneikaite E, Ellington MJ, Sriskandan S. 2021. Alterations in chromosomal genes nfsA, nfsB, and ribE are associated with nitrofurantoin resistance in Escherichia coli from the United Kingdom. Microb Genomics. 7:12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang S, Ji B, Zhang M, Gu J, Ma Y, Liu Y. 2021. Tetracycline-induced decoupling of symbiosis in microalgal-bacterial granular sludge. Environ Res. 197:111095. [DOI] [PubMed] [Google Scholar]
- Westhoff S, van Leeuwe TM, Qachach O, Zhang Z, van Wezel GP, Rozen DE. 2017. The evolution of no-cost resistance at sub-MIC concentrations of streptomycin in Streptomyces coelicolor. ISME J. 11(5):1168–1178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wistrand-Yuen E, Knopp M, Hjort K, Koskiniemi S, Berg OG, Andersson DI. 2018. Evolution of high-level resistance during low-level antibiotic exposure. Nat Commun. 9(1):1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yu D, Ellis HM, Lee EC, Jenkins NA, Copeland NG, Court DL. 2000. An efficient recombination system for chromosome engineering in Escherichia coli. Proc Natl Acad Sci U S A. 97(11):5978. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data underlying this article are available in the article and its online supplementary material. Fastq files with whole-genome sequences of resistant mutants have been uploaded at NCBIs SRA database with the bioproject accession number PRJNA906735.